drugset / Trial / NCT02819921

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

NCT02819921

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The purpose of this study is to determine if desvenlafaxine was effective in decreasing the frequency and severity of hot flashes in breast cancer patients taking tamoxifen.

Timeline

Start
2017-11-10
Primary completion
2019-03-15
Completion
2019-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 50 mg Oral
Subject Desvenlafaxine Other / unclassified 100 mg Oral

Indications